US Patent 7,438,927 for Gabapentin Gastric-Retained, Swellable-Polymer Release: What It Covers and How It Blocks Competition

US 7,438,927 is a US method-of-treatment patent built around a single technical thesis: gabapentin is delivered in a fed-state “gastric retained” dosage form that swells freely via a single swellable hydrophilic polymer matrix, and releases gabapentin by diffusion over at least 5 hours while leaving a high fraction of drug in the dosage form after 1 hour. The claims then ladder into practical admin regimens (once or twice daily, with meals), specific polymer choices, optional gas-generation structures, and downstream diffusion/release performance targets.

What are the claim anchors (core technical requirements)?

The patent’s independent claim family is centered on a dosage form architecture plus release and retention performance. While there are three independent-method groupings (epilepsy, neuropathic pain, and administration method), they share the same mechanical drug-delivery construct.

Independent-method claim 1 (epilepsy) and the shared technical “platform”

Claim 1 requires all of the following (summarized into elements):

Element	Claim requirement (verbatim concept)
Therapeutic use	Treating epilepsy in a mammal
Gabapentin dose range	Daily dose about 200 mg to about 4000 mg
Dosage form type	Gastric retained dosage form administered in a fed mode induced state
Matrix architecture	Single polymer matrix comprising at least one swellable hydrophilic polymer
Swelling behavior	Polymer swells in a dimensionally unrestrained manner by imbibing water to increase its size and promote gastric retention
Release mechanism/timing	Upon contact with water, gabapentin is released by diffusion from the dosage form over at least five hours
1-hour retention performance	At least 40 wt% of gabapentin is retained in the dosage form one hour after administration

Independent claims 17 and 33 recite the same delivery platform with different therapeutic indications and/or dose ranges.

Independent-method claim 17 (neuropathic pain)

Claim 17 uses the same delivery platform with neuropathic pain and a different daily dose band: about 100 mg to about 4800 mg.

Independent-method claim 33 (administration method)

Claim 33 is the broadest “administration method” framing and uses the same platform but removes the explicit disease diagnosis in the independent claim. It is still constrained to:

about 100 mg to about 4800 mg gabapentin daily
gastric retained, fed-mode induced administration
single swellable hydrophilic polymer matrix
diffusion release of at least 5 hours
≥ 40 wt% retained at 1 hour

What is actually claimed beyond the platform (scope expansion via dependent claims)?

The remainder of the claim set expands enforceable scope by (1) dosing schedule, (2) combination therapy, (3) narrower dose sub-ranges, (4) release distribution across GI segments, (5) delivery fraction over time, (6) polymer identities and molecular weights/viscosities, (7) optional gas generation/gas-matrix structures, and (8) explicit formulation archetypes (bilayered adhesive tablet; membrane sachet; capsule; tablet matrix composition).

1) Administration timing and meal coupling

Claim cluster	Requirement
Once-daily	Claim 2 (epilepsy) requires once-daily
Twice-daily	Claim 4 (epilepsy) requires twice-daily
Meal administration	Claims 3 and 5 require with a meal for once- and twice-daily variants respectively; similarly Claims 19 and 21 for neuropathic pain

For independent-method claim 33, the parallel regimen claims are 34-37.

Practical implication for design-around: a competitor using the same gastric-retained swellable diffusion concept but with different dosing frequency (e.g., TID) is not necessarily outside the independent platform if disease and other elements are satisfied; however, the dependent claims give the patentee additional “fallback” positions for common clinical regimens.

2) Combination therapy

Epilepsy: Claim 6 adds “one or more additional anti-epileptics or anticonvulsants.”
Neuropathic pain: Claim 22 adds “therapeutic agents selected from the group consisting of anticonvulsants, tricyclic antidepressants, opioids, and levodopa.”
Independent claim 33 has disease-targeting dependent claims (38, 39) but not a separate independent combination cluster in the text provided.

3) Narrower daily dose bands (numeric subranges)

For epilepsy (Claim 7: 600-2700 mg; Claim 8: 900-1800 mg). For neuropathic pain (Claim 23: 300-3600 mg; Claim 24: 900-2400 mg). For administration (Claim 63: 300-3600 mg; Claim 64: 900-2400 mg).

Practical implication: these dependent bands can matter for infringement defenses focused on dose outside the broad “about” ranges. They also create litigation “tripwires” for dose marketing and label directions.

4) Targeted GI release distribution

Claim 9 (epilepsy) requires release to stomach, duodenum and small intestine.
Claim 25 (neuropathic pain) uses the same distribution language.
Claim 40 (administration) repeats the distribution requirement.

Practical implication: if a competitor’s system releases mainly in stomach and colon or primarily in small intestine only, the patentee’s dependent claim coverage narrows.

5) Delivery fraction over time (wt% delivered vs retained)

Claim 10 (epilepsy) requires at least 80 wt% delivered over about 5-12 hours.
Claim 26 (neuropathic pain) requires at least 85 wt% delivered over about 5-12 hours.
Claim 41 (administration) requires at least 80 wt% delivered over about 5-12 hours.

Important structural relationship: the independent claim already sets ≥40 wt% retained at 1 hour. These dependent claims further constrain overall fraction delivered and delivery window, tying performance to a specific kinetic profile.

6) Polymer identity (and explicit material families)

Claim 11 (epilepsy) selects swellable hydrophilic polymer from:
- polyethylene oxides,
- alkyl substituted cellulose materials,
- combinations.
Claim 27 repeats this for neuropathic pain.
Claim 42 repeats for administration.

This is reinforced by molecular weight and viscosity constraints in later dependent claims.

7) Polymer performance and composition details

The claim text includes explicit swelling and polymer spec targets:

Swelling: Claims 48, 49, 50 require polymer swelling to approximately 115% of original volume within 1 hour.
Molecular weight of hydrophilic polymer: Claims 54, 55, 56 require about 4×10³ to about 1×10⁷.
PEO molecular weight: Claim 57 requires PEO about 2,000,000 to about 7,000,000 daltons.
HPMC viscosity: Claims 58 and 59 require hydroxypropylmethylcellulose viscosity about 4000 cps to about 100,000 cps (1% aqueous solution).

Practical implication: these dependent specs create additional claim coverage for variants that match the likely internal formulation parameters (PEO high molecular weight and HPMC viscosity).

8) Optional gas generation architecture

Claim 12 (epilepsy), 28 (neuropathic pain), and 43 (administration) add “gas generating agent.”
Claims 13, 29, 44 add gabapentin in a membrane sachet with the gas generating agent.

Practical implication for competitive landscape: the independent platform claims do not require gas generation, but gas-generation features create specific claim islands that are harder to avoid if a competitor uses similar buoyancy/expandability strategies to induce gastric retention.

9) Form factor and structure: adhesive tablets, multilayers, and capsules

Adhesive tablet: Claims 14 and 30 for epilepsy and neuropathic pain, and Claim 45 for administration.
Capsule: Claims 15 and 31 and dependent variants 46.
Tablet matrix composition:
- Claims 16 and 32: tablet matrix comprised of poly(ethylene oxide) and hydroxypropylmethylcellulose.
- Claim 47 repeats for administration.

There is also a duplication/formatting inconsistency in claim text for some capsule/tablet phrasing; the scope intent remains the same: specific dosage architecture options map to additional dependent claim coverage.

10) Mammal identity and diagnosis

Human mammal: Claims 60 (epilepsy), 61 (neuropathic pain), 62 (administration).
Diagnosis language in claim 33 dependent form:
- Claim 38: mammal diagnosed with or suffering from epilepsy
- Claim 39: mammal diagnosed with or suffering from neuropathic pain

These dependent claims matter for enforcement strategy in US where labeling and clinical indication drive contributory and induced infringement theories.

Where does the claim language place pressure on design-around strategies?

The independent claim set has a tight coupling of: 1) fed-mode induced administration, 2) gastric retained behavior driven by unrestrained swellable hydrophilic polymer, 3) diffusion-based release over a minimum timeline (≥ 5 hours), 4) high initial retention (≥ 40 wt% remaining at 1 hour).

That combination is the main barrier. Design-around routes in the real world usually target at least one axis:

A) Retention kinetics

To avoid literal infringement of the independent platform, a product would need to avoid meeting ≥40 wt% retained at 1 hour or avoid diffusion release over ≥5 hours. Claims 10/26/41 also constrain delivered fraction.

B) Mechanism (diffusion) and release profile

If a product’s release is primarily erosion-driven, dissolution-controlled, or triggered by a different mechanism (even if swelling still occurs), it can potentially avoid the “released by diffusion” element. Dependent claims further constrain delivery timing windows.

C) Swelling behavior and matrix “single polymer matrix”

Independent claims require a single polymer matrix and a polymer that swells “dimensionally unrestrained” by water imbibing.

A competitor using a multilayer structure where the swellable polymer is segregated, or uses a restrained swelling strategy, may avoid the “dimensionally unrestrained manner” and/or “single polymer matrix” element. Dependent claims do list bilayered or multilayered adhesive tablets, but those are optional scope expansions, not required by the independent claim.

D) Gastric retention strategy

The claims tie gastric retention to swelling-induced size increase. If gastric retention is driven by a different mechanism (e.g., size-expandable via gas, floating shell without swellable matrix, mucoadhesion without free swelling), the independent “swellable hydrophilic polymer” and “unrestrained manner” elements are vulnerable.

How broad is the scope across indications and dosing?

US 7,438,927 gives the patentee two primary therapeutic claim tracks:

Epilepsy (Claim 1 + dependent ecosystem)
Neuropathic pain (Claim 17 + dependent ecosystem)

It also provides a third “independent spine” for administration (Claim 33) that can be paired with dependent indication claims for epilepsy or neuropathic pain.

Dose scope:

Epilepsy independent: 200 to 4000 mg daily
Neuropathic independent: 100 to 4800 mg daily
Administration independent: 100 to 4800 mg daily

Both independent tracks share the same performance constraints (diffusion release, ≥5 hours, ≥40 wt% retained at 1 hour). That creates a consistent enforceable delivery platform regardless of indication.

US patent landscape: how this claim strategy maps to likely infringement risk (high-level, structure-driven)

Because the claims are performance- and mechanism-led rather than purely composition-led, the patent landscape effect is shaped by which competitors build “gastric retained” gabapentin formulations with swellable hydrophilic polymer matrices.

What products are most exposed to infringement theories

Products that plausibly match all or most of these traits:

gabapentin in a fed-state gastric retained system,
single swellable hydrophilic polymer matrix,
swelling to ~115% within 1 hour (if matching dependent specs),
diffusion-controlled release over ≥5 hours,
high early drug retention in the dosage form (≥40 wt% at 1 hour),
optional but common add-ons: meal-timed once-daily/twice-daily regimens, PEO/HPMC matrices, and expandable/gas-generating components.

In practice, this clusters exposure around “extended-release, gastric retained gabapentin” technical families where swelling kinetics and diffusion are central design parameters.

Where infringement risk drops

Coverage narrows if a competitor changes any critical element:

moves to non-diffusion release (erosion/dissolution),
fails to meet the retention criterion at 1 hour,
removes the “unrestrained” swelling behavior or the “single polymer matrix” requirement,
does not rely on the specified swelling mechanism to induce gastric retention,
uses different polymer systems outside the listed families (this can still avoid dependent claims, but not necessarily the independent claim if the independent polymer definition is met).

Key takeaway: what competitors must clear to avoid literal infringement

US 7,438,927 is not an “obvious use-based” method patent. It is a delivery-platform patent. Literal infringement hinges on the technical combination of swelling-based gastric retention plus diffusion release plus early drug retention in the dosage form.

Key Takeaways

US 7,438,927 claims a gastric retained gabapentin method built on a single swellable hydrophilic polymer matrix that swells freely by water imbibing in a fed-mode state.
The independent claim performance core is diffusion release over at least 5 hours and ≥40 wt% gabapentin retained in the dosage form 1 hour after dosing.
Dependent claims add enforceable islands for once- or twice-daily meal regimens, GI release into stomach/duodenum/small intestine, and high delivered fraction (≥80 wt% over ~5-12 hours).
The patent further tightens scope with gas generating agents (including membrane sachet configurations), adhesive bilayer/multilayer tablet architectures, capsules, and specific polymer formulations such as PEO + HPMC plus polymer spec windows (e.g., PEO 2,000,000 to 7,000,000 Da; HPMC viscosity 4,000 to 100,000 cps).
Competitive exposure is highest for gabapentin gastric-retained ER products whose formulation and dissolution kinetics replicate the claimed swelling, diffusion, and retention parameters.

FAQs

Does US 7,438,927 require a gas generating agent?
No. Gas generating agents appear only in dependent claims (e.g., claims 12, 13, 28, 29, 43, 44 in the provided claim text).
What is the single most constraining performance parameter in the independent claims?
At least 40 wt% of gabapentin is retained in the dosage form one hour after administration, coupled with diffusion release over at least five hours.
Can a product infringe if it releases into the small intestine but not the duodenum?
That would avoid dependent claims requiring release into stomach, duodenum and small intestine (claims 9, 25, 40), but independent claim infringement still depends on satisfying the independent elements.
Are there claim targets for polymer identity beyond “swellable hydrophilic polymer”?
Yes. Dependent claims specify hydrophilic polymer selections (polyethylene oxides and alkyl substituted cellulose materials) and further narrow with swelling to ~115%, polymer molecular weight, and a PEO + HPMC matrix embodiment.
Is the patent limited to epilepsy and neuropathic pain only?
The claim set explicitly covers those two indications via independent claim families (claims 1 and 17) and through the administration method plus diagnosis-dependent claims (claims 38 and 39 for claim 33).

References

[1] United States Patent 7,438,927, “Method of treating epilepsy or neuropathic pain using gabapentin in a gastric retained dosage form” (claim text provided in prompt).

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2002348828	⤷ Start Trial
Australia	2005267738	⤷ Start Trial
Australia	2006332690	⤷ Start Trial
Canada	2464322	⤷ Start Trial
Canada	2575555	⤷ Start Trial
Canada	2635466	⤷ Start Trial
China	101484153	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,438,927

Summary for Patent: 7,438,927